Sexually transmitted diseases (STIs) are the most frequently reported bacterial infections of humans in the United States, surpassing all other infections combined, including respiratory and enteric infections. Among STIs, Chlamydia trachomatis (CT) infections are the most frequently reported bacterial infections. CT co- infections with the gonococcus (GC), Neisseria gonorrhoeae, are relatively frequent. Together these pathogens are responsible for most cases of pelvic inflammatory disease (PID), which may lead to sequelae that profoundly impact female reproductive health: tubal factor infertility (TFI) and life-threatening ectopic pregnancy. With respect to GC infections, resistance to common antibiotics is a growing concern. While NAAT-based diagnosis of these 2 infections is highly specific and sensitive, it fails to address 2 major issues: 1) a positive diagnosis often necessitates that the patient returns for a second visit for treatment, and 2) currently available tests do not discriminate between infection and disease, a significant problem, particularly in the case of asymptomatic infections. Project 2 aims to identify serum biomarkers that can be diagnostic and/or predictive of CT infection and CT/GC co-infection. Serum is a convenient physiological sample that is easily and inexpensively obtained, is highly versatile with respect to laboratory testing, and relatively stable and easy to store. As such serum has been used extensively for a multiplicity of medical purposes with great success. Although serology has often been dismissed as a useful tool in the detection of CT and GC, we propose to develop two assay systems in Project 2 that will take serology to a new level where CT and GC are concerned. We will first use a highly specific ELISA system to detect antibody titers to a variety of outer membrane or secreted proteins of CT and GC that may be diagnostic or predictive of CT or GC infection and co-infection and subsequent pathology. Preliminary studies suggest that antibody responses to 3 CT outer membrane proteins are associated with PID. A second objective will be to identify microRNAs, small RNAs that are made by the host in response to a variety of stimuli, that may be exploited as specific biomarkers of CT or GC infection and co-infection and subsequent disease. While the overarching objective of this project is strongly translational, with the future development of highly sensitive and specific point-of-care and/or predictive tests for STIs and associated pathologies as the primary focus, it is also probable that our findings will uncover biomarkers that are revealing of underlying mechanisms of pathogenesis. Although these will not be investigated here, Project 2 findings will enhance and complement studies of STI pathogenesis undertaken in Projects 1 and 3 concerning the role of human genetic variance and host response, the role of the microbiota and the pathogenomics of CT and GC in the production of pathology.

Public Health Relevance

Sexually transmitted infections are often silent. The diseases associated with these infections are also often asymptomatic. Improved and novel biomarkers of infection and disease will aid faster and more effective diagnosis and therapy, reducing the burden of long-term disease. The research in this proposed Project is directly relevant to the NIH mission as it directly aims to promote health by improving diagnosis, reducing risk to the unintended adverse disease sequelae of STIs and improving the quality of life for people who are at risk of STIs.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
2U19AI084044-06
Application #
8769307
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
6
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Maryland Baltimore
Department
Type
DUNS #
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Tachedjian, Gilda; O'Hanlon, Deirdre E; Ravel, Jacques (2018) The implausible ""in vivo"" role of hydrogen peroxide as an antimicrobial factor produced by vaginal microbiota. Microbiome 6:29
Noyes, Noelle; Cho, Kyu-Chul; Ravel, Jacques et al. (2018) Associations between sexual habits, menstrual hygiene practices, demographics and the vaginal microbiome as revealed by Bayesian network analysis. PLoS One 13:e0191625
Wang, Liuyang; Pittman, Kelly J; Barker, Jeffrey R et al. (2018) An Atlas of Genetic Variation Linking Pathogen-Induced Cellular Traits to Human Disease. Cell Host Microbe 24:308-323.e6
Palmer, Allison; Criss, Alison K (2018) Gonococcal Defenses against Antimicrobial Activities of Neutrophils. Trends Microbiol 26:1022-1034
Schroeder, Holly A; Nunn, Kenetta L; Schaefer, Alison et al. (2018) Herpes simplex virus-binding IgG traps HSV in human cervicovaginal mucus across the menstrual cycle and diverse vaginal microbial composition. Mucosal Immunol 11:1477-1486
Ragland, Stephanie A; Humbert, Mar?a V; Christodoulides, Myron et al. (2018) Neisseria gonorrhoeae employs two protein inhibitors to evade killing by human lysozyme. PLoS Pathog 14:e1007080
van Houdt, Robin; Ma, Bing; Bruisten, Sylvia M et al. (2018) Lactobacillus iners-dominated vaginal microbiota is associated with increased susceptibility to Chlamydia trachomatis infection in Dutch women: a case-control study. Sex Transm Infect 94:117-123
Cornejo, Omar E; Hickey, Roxana J; Suzuki, Haruo et al. (2018) Focusing the diversity of Gardnerella vaginalis through the lens of ecotypes. Evol Appl 11:312-324
Tyssen, David; Wang, Ying-Ying; Hayward, Joshua A et al. (2018) Anti-HIV-1 Activity of Lactic Acid in Human Cervicovaginal Fluid. mSphere 3:
Oehlers, Stefan H; Flores, Maria Vega; Hall, Christopher J et al. (2017) A whole animal chemical screen approach to identify modifiers of intestinal neutrophilic inflammation. FEBS J 284:402-413

Showing the most recent 10 out of 54 publications